Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-a
Phase 3 · Cholangiocarcinoma |
TransThera Sciences (Nanjing), Inc | Tinengotinib 8 mg, Tinengotinib 10 mg, P |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|